PMC:4939752 / 39738-39945 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/4939752","sourcedb":"PMC","sourceid":"4939752","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4939752","text":"Ocrelizumab(2H7; PRO70769)Phase III Genentech/Roche/BiogenType ImAb Humanized IgG1 Ocrelizumab (47 patients of Relapsed/Refractory FL, ORR 38%)750 [33] High ADCCLow CDC Second (Humanized and FullyHuman)","divisions":[{"label":"td","span":{"begin":0,"end":35}},{"label":"td","span":{"begin":37,"end":68}},{"label":"td","span":{"begin":70,"end":84}},{"label":"td","span":{"begin":86,"end":154}},{"label":"td","span":{"begin":156,"end":172}}],"tracks":[]}